2024 CUDA | Dr. Jianming Guo: Addressing Clinical Needs of Prostate Cancer in China – Exploring Treatment Prospects from Diagnosis to Surgery

2024 CUDA | Dr. Jianming Guo: Addressing Clinical Needs of Prostate Cancer in China – Exploring Treatment Prospects from Diagnosis to Surgery

From August 8-11, 2024, the Annual Meeting of the Chinese Urological Association (CUDA) was held in Xi'an, hosted by the Chinese Medical Doctor Association and its Urological Physician Branch, organized by Xijing Hospital of the Air Force Medical University, and co-hosted by the Urology Physician Branch of the Shaanxi Medical Doctor Association. Under the theme "Healthy China, Urology First," the conference showcased the latest advancements in urology from a broad perspective and multiple dimensions. On the first day of the academic sessions (August 9), Urology Frontier interviewed the conference host, Dr. Jianming Guo from Zhongshan Hospital affiliated with Fudan University, to share insights on the unmet clinical needs of prostate cancer in China, recent breakthroughs in clinical research, and future exploration directions.
International Lung Cancer Conference | Dr. Wentao Fang: Neoadjuvant Therapy for Locally Advanced NSCLC

International Lung Cancer Conference | Dr. Wentao Fang: Neoadjuvant Therapy for Locally Advanced NSCLC

Treating locally advanced lung cancer is a significant clinical challenge, with perioperative treatment being key to improving patient outcomes. At the 2024 International Lung Cancer Conference (CLC 2024), Dr. Wentao Fang from Shanghai Chest Hospital delivered a presentation titled "Neoadjuvant Therapy for Locally Advanced NSCLC." This article provides a brief overview of his report.
2024 CUDA | Dr. Tao Xu: Addressing the Challenges of Prostate Cancer Androgen Deprivation Therapy, Optimal Treatment Strategies, and Future Directions

2024 CUDA | Dr. Tao Xu: Addressing the Challenges of Prostate Cancer Androgen Deprivation Therapy, Optimal Treatment Strategies, and Future Directions

Androgen deprivation therapy (ADT), also known as castration therapy, involves lowering male hormone levels through surgery or medication to treat prostate cancer. Recently, the 2024 Annual Meeting of the Chinese Urological Association (CUDA) was successfully held in Xi'an. Following the event, Urology Frontier invited Dr. Tao Xu, Director of Urology at Peking University People's Hospital, to share insights on the challenges and developments in prostate cancer androgen deprivation therapy.
Dr. Yew Kuo Chao: The future treatment direction of MAFLD will be more personalized

Dr. Yew Kuo Chao: The future treatment direction of MAFLD will be more personalized

Recently, the Combined GlHep&SHC 2024 was successfully held in Singapore. This conference covers various aspects of liver disease research and provides an interdisciplinary communication platform for experts and scholars. During the conference, Hepatology Digest invited Dr. Yew Kuo Chao, a senior consultant at Tan Tock Seng Hospital, Singapore, to discuss topics related to metabolic associated fatty liver disease (MASLD).
2024 CUDA丨Dr. Weijun Qin: Unprecedented CUDA Conference Advances Urology, Innovations in Xenotransplantation Enhance Patient Benefits

2024 CUDA丨Dr. Weijun Qin: Unprecedented CUDA Conference Advances Urology, Innovations in Xenotransplantation Enhance Patient Benefits

From August 8th to 11th, 2024, the Annual Meeting of the Urology Physicians Branch of the Chinese Medical Doctor Association (CUDA) was held in Xi'an. The conference was hosted by the Chinese Medical Doctor Association and the Urology Physicians Branch, organized by Xijing Hospital of the Air Force Medical University, and co-organized by the Urology Physicians Branch of the Shaanxi Medical Doctor Association. Under the banner of "Healthy China, Urology Takes the Lead," the conference brought together many of the latest achievements in urology. At the conference, Urology Frontier interviewed the conference's executive chairman, Dr. Weijun Qin of Xijing Hospital, Air Force Medical University, who summarized the conference's innovations and significance, and shared breakthroughs in xenotransplantation and advancements in prostate cancer diagnosis and treatment.
2024 CUDA丨Dr. Sujun Han: Prostate Cancer Quality Control Indicators Aid in Standardizing Diagnosis and Treatment, Enhancing Both Survival and Quality

2024 CUDA丨Dr. Sujun Han: Prostate Cancer Quality Control Indicators Aid in Standardizing Diagnosis and Treatment, Enhancing Both Survival and Quality

Prostate cancer is the most common malignancy of the male genitourinary system. Compared to Western countries, a larger proportion of prostate cancer patients in China are diagnosed at intermediate to advanced stages, leading to poorer prognosis. At the recent 2024 Annual Meeting of the Urology Physicians Branch of the Chinese Medical Doctor Association (CUDA), Urology Frontier invited Dr. Sujun Han from the National Cancer Center/Cancer Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College, to discuss the background of the development of single-disease quality control indicators for prostate cancer, the value of promoting standardized diagnosis and treatment, and treatment strategies for advanced patients, with the goal of improving both survival rates and quality of life for prostate cancer patients.
2024 CUDA丨Dr. Nianzeng Xing: Special Sessions Propel New Productivity in Urology, Highlighting the Spirit of International Collaboration in Healthcare

2024 CUDA丨Dr. Nianzeng Xing: Special Sessions Propel New Productivity in Urology, Highlighting the Spirit of International Collaboration in Healthcare

In the journey toward a "Healthy China," urology leads the way. From August 9th to 11th, 2024, the eagerly anticipated 2024 Annual Meeting of the Urology Physicians Branch of the Chinese Medical Doctor Association was grandly held in Xi'an. With a broad global perspective, the conference showcased the latest achievements in the field of urology from multiple angles, paving the way for a new chapter in China's healthcare construction alongside urology professionals nationwide. After the event, Urology Frontier had the honor of interviewing the conference chairman, Dr. Nianzeng Xing, Vice President of the Cancer Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College, who shared insights on the conference highlights, Chinese initiatives, and the training of young professionals.
2024 COMB丨Dr. Songqing Ye: Exploring the Development of CDK4/6 Inhibitors, ADCs, and Immunotherapy in Early-Stage Breast Cancer

2024 COMB丨Dr. Songqing Ye: Exploring the Development of CDK4/6 Inhibitors, ADCs, and Immunotherapy in Early-Stage Breast Cancer

From August 2-4, 2024, the 7th Oncology Precision Diagnosis and Treatment Conference and the 10th Breast Cancer Individualized Treatment Conference (COMB), organized by the China Cancer Foundation and Beijing Breast Disease Prevention Society, was grandly held in Beijing. The conference brought together the latest advances in individualized precision treatment for breast cancer in China, providing a broad platform for promoting new concepts, developing new technologies, and creating new models in the breast cancer field. With the recent advancements in breast cancer precision medicine, CDK4/6 inhibitors (CDK4/6i), immunotherapy drugs, and antibody-drug conjugates (ADCs) have significantly improved the survival benefits for breast cancer patients. Oncology Frontier conducted an exclusive interview with Dr. Songqing Ye from Fujian Provincial Hospital to discuss the current landscape and trends in the development of new drugs for precision treatment of early-stage breast cancer.
2024 COMB丨Dr. Yanxia Zhao: Comprehensive Considerations for Radiotherapy Exemption and Hypofractionated Radiotherapy in Clinical Practice

2024 COMB丨Dr. Yanxia Zhao: Comprehensive Considerations for Radiotherapy Exemption and Hypofractionated Radiotherapy in Clinical Practice

From August 2-4, 2024, the 7th Oncology Precision Diagnosis and Treatment Conference and the 10th Breast Cancer Individualized Treatment Conference (COMB), organized by the China Cancer Foundation and Beijing Breast Disease Prevention Society, was grandly held in Beijing. The conference gathered the latest advancements in individualized precision treatment for breast cancer in China and provided insights into the precise implementation of postoperative radiotherapy for breast cancer. At the event, Oncology Frontier invited Dr. Yanxia Zhao from Union Hospital, Tongji Hospital of Huazhong University of Science and Technology, to interpret the standards for exempting radiotherapy post-surgery, analyze the advantages of hypofractionated radiotherapy, and share tips on managing radiotherapy-related complications.
AIDS Interview | Enhancing Immune Protection for HIV-Positive Individuals: Tailored Vaccination Strategies

AIDS Interview | Enhancing Immune Protection for HIV-Positive Individuals: Tailored Vaccination Strategies

In the field of AIDS prevention and treatment, tailored immunization strategies for HIV-positive individuals are becoming crucial for improving patients' quality of life and prolonging their lifespan. At the 25th International AIDS Conference (AIDS 2024), Dr. Anna Maria Geretti from the Institute of Infection and Global Health, University of Liverpool presented an insightful report on this topic and subsequently engaged in an extensive interview with " Infectious Disease Frontier"(IIDF). She emphasized the importance of ensuring that HIV-positive individuals receive appropriate vaccination recommendations and pointed out the deficiencies in comprehensiveness and personalization in current guidelines. Dr. Geretti elaborated on the key factors to consider when formulating personalized vaccination strategies, such as immune status, viral load, and CD4+ T-cell count, which directly influence vaccine selection and effectiveness. Furthermore, she shared the latest research findings and vaccination recommendations for vaccines against hepatitis B, shingles, pneumococcal disease, and human papillomavirus (HPV), providing a more scientific and comprehensive protection plan for HIV-positive individuals.